RE: GSK appointments - thoughts22 Jul 2022 20:48
Evening Sixth - I'd guess it's highly unlikely unless one of our chaps was offered a position as part of any merger deal. Perhaps it could happen but not in the here and now.
Whilst on the subject of GSK, over on the GSK forum a poster (Newtrader87) has posted an article from the FT on the GSK/Haleon split. The bit that's maybe of interest to ouselves relates to how GSK proves to investors that it can use the extra cash and balance-sheet strength from the separation to refill its drug pipeline and push revenue and profit margins higher -
"The acquisition of the Nasdaq-listed rare blood cancer specialist Sierra Oncology earlier this year, for $1.9 billion, is a blueprint for the type of deal that GSK will look for with its richer cash resources. Sierra’s lead product is momelotinib, a drug for myelofibrosis, a rare type of bone marrow cancer, and anaemia, a symptom of the disease. Unlike early-stage treatments, there is a real prospect of the deal contributing to revenues in the near term.
A submission to America’s Food and Drug Administration for regulatory approval in the US is expected in the second quarter of this year, before it is likely to begin generating sales next year. Analysts are forecasting peak revenues of $630 million (£525 million) by 2030.
Positive late-stage clinical trials in January had caused Sierra’s shares to almost double during the first four months of the year, even prior to the GSK deal, but market turmoil could thwart the chance to pick up other biotech companies more cheaply."
If they think a drug generating $630m in revenue per year is good, wait 'til they get 737 to market. Ker-bleedin'-chinggg.
Sign In
Follow the stocks
